)
Visual
earnings real time
Atea Pharmaceuticals (AVIR) investor relations material
Atea Pharmaceuticals Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary3 Dec, 2025
Clinical development progress
Patient recruitment target achieved for phase III C-BEYOND in North America; enrollment to be completed soon with 880 patients, results expected mid-2026.
C-FORWARD trial recruiting well outside North America, full enrollment anticipated mid-2026, results by end of next year.
New drug candidates AT-587 and AT-2490 from the nucleotide platform show strong in vitro antiviral activity, targeting hepatitis E in immunocompromised patients.
NDA filing for hepatitis C program planned for Q1 2027, with phase II/III data expected in 2027.
Phase III is a head-to-head study against standard of care, featuring an eight-week treatment regimen.
Market landscape and commercial strategy
Hepatitis C prevalence is rising, with over 4 million cases in the U.S. and 150,000 new cases annually, but only 100,000 treated each year.
Key opinion leaders and prescribers seek short-course, low DDI, convenient therapies to enable test-and-treat models.
Test-and-treat is gaining traction in the U.S. and Europe, aiming to treat patients immediately upon diagnosis to prevent loss to follow-up and further transmission.
U.S. market is highly concentrated, with 6,000 physicians responsible for 80% of DAA prescriptions.
Launch readiness includes both bottle and blister pack forms, with 20,000-30,000 treatments available at launch and low manufacturing costs.
Pricing, partnerships, and global outlook
Pricing strategy aims to be competitive with current market offerings across commercial and government segments.
No significant price difference expected between U.S. and Europe; U.K. recently announced a 25% price increase.
Seeking partnerships with companies experienced in antivirals or liver disease, especially in Europe and Japan, with expectations for robust double-digit royalties.
Ex-U.S. market opportunity estimated at around $1 billion.
How will test and treat drive HCV market growth?
Who funds HCV test and treat infrastructure?
Why is low DDI critical for HEV target patients?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Atea Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Next Atea Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for the treatment of viral diseases. The company's research and development efforts primarily target diseases such as hepatitis C, dengue, and COVID-19. Atea leverages its expertise in nucleoside and nucleotide therapeutics to create treatments aimed at addressing unmet medical needs in the antiviral space. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage